Steininger K, Boyd A, Dupke S, Krznaric I, Carganico A, Munteanu M, Neifer S, Schuetze M, Obermeier M, Arasteh K, Baumgarten A, Ingiliz P
Charité-Universitätsmedizin Berlin, Berlin, Germany.
Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM UMR_S 1136, Paris, France.
J Viral Hepat. 2017 Oct;24(10):832-839. doi: 10.1111/jvh.12707. Epub 2017 Apr 25.
Acute hepatitis C virus infection remains a major health concern in human immunodeficiency virus(HIV)-infected men who have sex with men (MSM). New direct-acting antiviral agent (DAA) combination therapy has not yet been approved for the treatment for acute hepatitis C virus(HCV), thereby potentially causing deferral of HCV treatment. Therefore, we aimed to study the course of liver disease after an episode of acute HCV. This study is a retrospective single-centre cohort of HIV-positive MSM with acute HCV infection. Liver fibrosis was estimated by Fibroscan and Fibrotest . Liver-related and non-liver-related outcomes were documented. Overall 213 episodes of acute HCV infection in 178 men were documented. Median follow-up for all included patients was 38.7 months. Spontaneous HCV clearance was found in 10.8% of patients, which was significantly associated with older age, lower HCV RNA levels, and higher ALT levels upon initial acute HCV diagnosis. Treatment with interferon-based therapy was initiated in 86.3% of cases, resulting in a sustained virological response(SVR) rate of 70.7%. After 3 years' follow-up, significant liver fibrosis of METAVIR F2 stage or higher was found in 39.4% of patients after first acute HCV diagnosis. Higher age, physician-declared alcoholism, and nonresponse to acute HCV therapy were independently associated with higher fibrosis stages. Ten patients died during the observation period (IR 1.4/100 patient-years) and four during interferon treatment. Significant liver fibrosis is a common finding in HIV-positive MSM following acute HCV infection despite high treatment uptake and cure rates, suggesting the need for close liver disease monitoring particularly if HCV treatment is deferred.
急性丙型肝炎病毒感染仍是感染人类免疫缺陷病毒(HIV)的男男性行为者(MSM)的一个主要健康问题。新型直接抗病毒药物(DAA)联合疗法尚未被批准用于治疗急性丙型肝炎病毒(HCV)感染,这可能会导致HCV治疗的延迟。因此,我们旨在研究急性HCV发作后的肝病病程。本研究是一项针对HIV阳性且患有急性HCV感染的MSM的回顾性单中心队列研究。通过Fibroscan和Fibrotest评估肝纤维化情况。记录与肝脏相关和非肝脏相关的结局。共记录了178名男性的213次急性HCV感染发作。所有纳入患者的中位随访时间为38.7个月。10.8%的患者出现HCV自发清除,这与年龄较大、初始急性HCV诊断时较低的HCV RNA水平以及较高的ALT水平显著相关。86.3%的病例开始使用基于干扰素的疗法进行治疗,持续病毒学应答(SVR)率为70.7%。经过3年的随访,首次急性HCV诊断后,39.4%的患者出现了METAVIR F2期或更高阶段的显著肝纤维化。年龄较大、医生诊断为酒精性肝病以及对急性HCV治疗无应答与更高的纤维化阶段独立相关。在观察期内有10名患者死亡(发病率为1.4/100患者年),在干扰素治疗期间有4名患者死亡。尽管治疗接受率和治愈率较高,但在HIV阳性的MSM中,急性HCV感染后出现显著肝纤维化是一个常见现象,这表明需要密切监测肝病情况,特别是在HCV治疗延迟的情况下。